{"id":"NCT01924533","sponsor":"AstraZeneca","briefTitle":"Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.","officialTitle":"A Randomized, Double-blinded, Placebo Controlled, Multicentre Phase III Study to Assess the Efficacy and Safety of Olaparib (AZD2281) in Combination With Paclitaxel, Compared to Placebo in Combination With Paclitaxel, in Asian Patients With Advanced Gastric Cancer (Including the Gastro-oesophageal Junction) Who Have Progressed Following First Line Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09-03","primaryCompletion":"2016-04-04","completion":"2023-03-27","firstPosted":"2013-08-16","resultsPosted":"2018-11-07","lastUpdate":"2024-03-22"},"enrollment":525,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Gastric Cancer"],"interventions":[{"type":"DRUG","name":"Olaparib","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Olaparib+ paclitaxel","type":"EXPERIMENTAL"},{"label":"Placebo+paclitaxel","type":"PLACEBO_COMPARATOR"}],"summary":"This study is a phase III, multi-centre study of olaparib in combination with paclitaxel, compared with placebo in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy. Patients will be from China, Japan , Korea and Taiwan.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"Survival contact from the date of randomization and then every 8 weeks following objective disease progression and in the 7 days following OS Data Cut off (DCO); Time point(s) at which outcome measure is assessed up to 4 years","effectByArm":[{"arm":"Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2","deltaMin":82,"sd":null},{"arm":"Placebo Tablets bd + Paclitaxel 80 mg/m^2","deltaMin":62,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0262"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":57,"countries":["China","Japan","South Korea","Taiwan"]},"refs":{"pmids":["29103871"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1856&filename=GOLD%20Study%20protocol-redacted.pdf","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D081BC00004&amp;attachmentIdentifier=65ef6d55-2b26-4d0d-a8d4-d96af57903de&amp;fileName=d081bc00004-study-synopsis_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":92,"n":262},"commonTop":["Neutropenia","Alopecia","Anaemia","Decreased appetite","Nausea"]}}